“Newcastle disease: control in different field challenges”.
Francisco Perozo DVM., MS., PhD. University of Zulia, Venezuela. Paris, France April 23 ‐ 25
For this talk… • Newcastle disease a worldwide problem for the Poultry Industry. • Newcastle disease Variants???? ‐‐ Important facts… • Solutions…. ‐ Key factors in the control. ‐ What to do depends on where you are… • Vaccination ‐ New technologies. ‐ VG/GA strain AVINEW alternative programs.
Why NDV? Because is the main concern for endemic countries…. still a threat for the NDV Free industry worldwide
16 weeks.… fallen birds, nervous signs, high mortality
NEWCASTLE DISEASE DISTRIBUTION 2013
America 2013
Southeast Asia 2013
Other countries 2013…..
Epidemiology and Prevalence •Mandatory report to the OIE. •Worldwide distribution. •Free countries still in risk due to globalization and international trade. •Prevalence data supported by Molecular epidemiology.
Question Are there NDV variant strains?
NO
Protectotype
Criteria to claim a variant is serology and cross protection
There are GENOTYPE DIFFERENCES that reflect in the virus behaviour, but not in the antigenic arrangements or serology.
• Genotypes V, VI , VII and VIII are the predominant genotypes circulating worldwide. • Genotype V South and Central America (1970s) •Genotype VI emerged in Asia in the 60’s and remained until Genotype VII took over 20 years ago… Genotype VIII is also present in Asia.
Do homologous genotype vaccines protect better?
Avian Dis. 2012 Sep;56(3):464-70. Characterization of live LaSota vaccine strain-induced protection in chickens upon early challenge with a virulent Newcastle disease virus of heterologous genotype. Cornax I1, Miller PJ, Afonso CL.
“Birds vaccinated an adequateoftiter of LaSota Properly done with vaccination healthy birds (Genotype II) strain live vaccine are fully protected from with current genotype commercial vaccines morbidity and mortality due toIIchallenge with (Genotype will deem adequate protection against any VII) ZJ1 strain NDV” genotype present in the field.
• Compared homologous versus heterologous genotype vaccination against a genotype VII and VIII lethal challenge • No difference in clinical protection was observed, despite the challenge virus, LaSota protected 100% • A decrease in viral shedding was observed in the homologous genotype groups when compared with LaSota group.
• Compared homologous versus heterologous genotype vaccination against a genotype V and VII lethal challenge • No difference in clinical protection despite the challenge virus, LaSota protected 100% • All vaccines decreased viral shedding. It was slightly lower (not P